HTG, Instituto Valenciano de Oncología partner on breast cancer recurrence

breast cancer
HTG and Instituto Valenciano de Oncología aim to create a score to predict breast cancer recurrence that is cheaper than alternatives already on the market.

HTG Molecular Diagnostics is teaming up with Spain’s Instituto Valenciano de Oncología to develop a score that will predict breast cancer recurrence using the former’s cancer biomarker panel.

The pair will base the score on the differences in gene expression in patients with low risk and high risk of recurrence, they said in a statement. The research collaboration will be based on HTG’s EdgeSeq Oncology Biomarker Panel, which profiles tumor samples using next-generation sequencing.

“While other breast cancer recurrence risk scores are available on market, we believe this effort could result in a more cost-effective, decentralized laboratory solution that may allow patients to more quickly make informed decisions regarding their treatments,” said HTG CEO T.J. Johnson, in the statement. HTG’s EdgeSeq technology is “well-suited” for this project as it uses a single tissue section from previously assessed cancer cases, he said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology

In addition to its Oncology Biomarker Panel, HTG offers a range of other EdgeSeq products, including a lymphoma panel, miRNA whole transcriptome assay and an immuno-oncology assay.

Other players that offer testing for breast cancer recurrence risk include Myriad Genetics, which launched a prognostic test earlier this year. The multigene test assesses the risk of recurrence following surgery and identifies patients who can safely skip chemotherapy.

Meanwhile, bioMérieux scored Medicare coverage for its breast cancer recurrence test in 2014. It quantifies the risk of recurrence and helps single out patients who may benefit from long-term hormone therapy.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.